Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma

Haematologica

Volumn 100, Issue 1, 2015, Pages 87-90

  Nitta, Hideaki ^a   Terui, Yasuhito ^a   Yokoyama, Masahiro ^a   Mishima, Yuko ^a   Nishimura, Noriko ^a   Ueda, Kyoko ^a   Kusano, Yoshiharu ^a   Tsuyama, Naoko ^a   Takeuchi, Kengo ^a   Kanda, Yoshinobu ^b   Hatake, Kiyohiko ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD CELL COUNT; BLOOD SMEAR; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PERIPHERAL MONOCYTE COUNT; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; AGED; BRAIN NEOPLASMS; CANCER STAGING; FOLLOW UP; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MONOCYTE; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84920176488     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114934     Document Type: Article

References (22)

1. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang, et al. Blood lymphocyte-to- monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with RCHOP. PLoS One. 2012;7(7):e41658.
2. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50(9): 696-702.
3. Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159(1):39-49.
4. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012; 26(3):97-106.
5. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502-9.
6. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53(4):575-80.
7. Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era. Haematologica 2013;99(1):125-30.
8. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157(3):321-30.
9. Rambaldi A, Boschini C, Delaini F, Oldani E, Rossi A, Barbui AM, et al. The peripheral blood lymphocyte to monocyte ratio at diagnosis is a potent outcome predictor in diffuse large B-cell lymphoma treated with R-CHOP: a long-term analysis on 973 patients receiving chemotherapy with or without rituximab. Blood. 2012;120: Abstract 155.
10. Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17(6):871-80.
11. Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al; European Mantle Cell Lymphoma Network. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013;24(8):2119-23.
12. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004;101(8):1760-6.
13. Harms DO, Janka-Schaub GE. Co-operative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL): longterm follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14(12):2234-9.
14. Tsurusawa M, Katano N, Yamamoto Y, Hirota T, Koizumi S, Watanabe A, et al. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group. Med Pediatr Oncol. 1999;32 (4):259-66.
15. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48 (3):452-8.
16. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumor-associated macrophages: undisputed stars of the inflammatory tumour microenviroment. Clin Exp Immunol. 2012;167(2): 195-205.
17. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872-81.
18. Chen C, Zhu YB, Shen Y, Zhu YH, Zhang XG, Huang JA. Increase of circulating B7- H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas. J Immunother. 2012;35(4):354-8.
19. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121 (23):4740-8.
20. Kobayashi M, Jeschke MG, Shigematsu K, Asai A, Yoshida S, Herndon DN, et al. M2b monocytes predominated in peripheral blood of severely burned patients. J Immunol. 2010;185(12):7174-9.
21. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-902.
22. Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014; 111(6):1072-9.